From candidate to default: the company has just been placed inside buyers' own purchasing systems
The model's full reasoning — Q3 2023 call → NOWe need to determine if management describes that the company has recently crossed into being an approved/specified/listed/etc. choice inside buyers' systems, such that future business can arrive without a discrete selling event, and that this status is new enough that most volume is still ahead. Look for evidence in the transcript. Management discusses launch in U.S., securing broad access to major retailers, contracts with pharmacies, etc. They mention being in over 14,000 retail outlets, having contracts with major retailers, and being available. But is that "approved, specified, listed, qualified, registered, reimbursed, or pre-authorized" inside buyers' purchasing systems? They have contracts with retailers, which is a form of being listed in their purchasing systems. However, the question distinguishes between ordinary selling relationships and being placed into a system where purchases flow without discrete selling. Retail contracts are typical distribution agreements. The key is whether management conveys that this access is new and that most volume is still ahead. Management says: "We achieved our prelaunch goal of securing broad access to our vaccine, the only protein-based non-mRNA option in the country." That is about access to retail channels. They also mention "contracts with the majority of major retailers" and "broad access." But is that a "buyer-side system" like a formulary or preferred supplier list? It's more like standard distribution. They also mention "being placed on a level playing field" and "fully stocked and available." They talk about market share being low-single digits but with potential. They say "we are seeing some early indicators that where we are positioned on a level playing field and fully stocked and available, we can effectively compete." That suggests they are now in the system, but it's early. However, the question asks if management conveys that the company has moved from candidate to default inside the routine pathway. They have contracts with retailers, but that is typical for any product. The distinction is whether the product is now automatically included in the purchasing process without needing to persuade each time. For retail pharmacies, once a contract is in place, the product is listed and can be ordered. That is a form of being listed.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| AZEK | The AZEK Company Inc. | Q2 2024 | 2024-05-08 | B+ |
| DXCM | DexCom, Inc. | Q4 2023 | 2024-02-08 | B+ |
| SCPH | scPharmaceuticals Inc. | Q3 2023 | 2023-11-08 | B |
| INGN | Inogen, Inc. | Q1 2023 | 2023-05-05 | F |
| HBB | Hamilton Beach Brands Holding Company | Q3 2022 | 2022-11-05 | C |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| MGNI | Magnite, Inc. | Q1 2022 | 2022-05-04 | D |
| AGIO | Agios Pharmaceuticals, Inc. | Q3 2018 | 2018-11-01 | C |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
PRIM · Q2 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this shift for the newly acquired T&D segment: after the Willbros acquisition (closed June 1, 2018), the T&D Group gained access to major utilities that had been hesitant due to prior financial concerns. With Primoris as parent, they signed new awards from the 3 largest electrical utilities (one announced MSA, two not yet announced), allowing work to flow under existing relationships without repeated persuasion. Management explicitly ties this to the recent acquisition and notes the MSA backlog now at $1.1 billion (first time exceeding $1 billion), with one-year estimated MSA revenue at $1.1 billion and continued growth expected.
AGIO · Q3 2018 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, qua...YES The transcript shows management describing exactly this transition for TIBSOVO. Steve Hoerter states that the company launched in July 2018 and is now receiving reimbursement with “no payer-related coverage issues,” with the payer mix (60% Medicare, 35% commercial) reflecting routine placement in those systems. He further notes that initial prescriptions are being written by over 100 unique prescribers and that awareness is already above 90%, confirming the product has moved from candidate status into the reimbursement and purchasing pathways. Because the launch is only a few months old at the time of the call, the $4.
AZEK · Q2 2024 → YESThe question is about whether management describes that the company has recently crossed from being a candidate that buyers must be persuaded to consider into being an approved, specified, listed, etc...YES The transcript shows management describing recent and incremental shelf-space gains in both pro and retail channels as a new development that will support growth in 2025, with investments planned for Q4 to enable these gains. This is framed as moving beyond prior years' steady execution into fresh wins that create a tailwind for future 2025 volume, where the company is now positioned to benefit from expanded availability in buyer systems (catalogs, dealer networks, and retail displays) without needing to re-persuade for each order.